Abstract:Purpose of review: Primary mitochondrial disease is a highly heterogeneous but collectively common inherited metabolic disorder, affecting at least one in 4300 individuals. Therapeutic management of mitochondrial disease typically involves empiric prescription of enzymatic cofactors, antioxidants, and amino acid and other nutrient supplements, based on biochemical reasoning, historical experience, and consensus expert opinion. As the field continues to rapidly advance, we review here the preclinical and clinical evidence, and specific dosing guidelines, for common mitochondrial medicine therapies to guide practitioners in their prescribing practices. Recent findings: Since publication of Mitochondrial Medicine Society guidelines for mitochondrial medicine therapies management in 2009, data has emerged to support consideration for using additional therapeutic agents and discontinuation of several previously used agents. Preclinical animal modeling data have indicated a lack of efficacy for vitamin C as an antioxidant for primary mitochondrial disease, but provided strong evidence for vitamin E and N-acetylcysteine. Clinical data have suggested L-carnitine may accelerate atherosclerotic disease. Long-term follow up on L-arginine use as prophylaxis against or acute treatment for metabolic strokes has provided more data supporting its clinical use in individuals with mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome and Leigh syndrome. Further, several precision therapies have been developed for specific molecular causes and/or shared clinical phenotypes of primary mitochondrial disease. Summary: We provide a comprehensive update on mitochondrial medicine therapies based on current evidence and our single-center clinical experience to support or refute their use, and provide detailed dosing guidelines, for the clinical management of mitochondrial disease. The overarching goal of empiric mitochondrial medicines is to utilize therapies with favorable benefit-to-risk profiles that may stabilize and enhance residual metabolic function to improve cellular resiliency and slow clinical disease progression and/or prevent acute decompensation.

Mitochondrial Diseases: Hope for the Future

Therapeutic and tampering approaches for mitochondrial associated diseases

Nuclear Genes and Mitochondrial Genes Associated with Mitochondrial Diseases

Therapies for mitochondrial diseases and current clinical trials

Treatment for Mitochondrial Diseases.

Current and Emerging Clinical Treatment in Mitochondrial Disease

Clinical Therapeutic Management of Human Mitochondrial Disorders

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

Mitochondrial dysfunction: mechanisms and advances in therapy

Mitochondrion and Its Related Disorders: Making a Comeback

Genetics of mitochondrial diseases: Current approaches for the molecular diagnosis

Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine

Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines

Mitochondrial diseases and mtDNA editing

Emerging Multi-omic Approaches to the Molecular Diagnosis of Mitochondrial Disease and Available Strategies for Treatment and Prevention

Therapeutic Approaches to Treat Mitochondrial Diseases: “One-Size-Fits-All” and “Precision Medicine” Strategies

Mitochondria and vision – a life in mitochondria always on the move

The special considerations of gene therapy for mitochondrial diseases

Mitochondrial diseases in adults

Illuminating mitochondrial translation through mouse models

A Clinical-Pathophysiological Perspective